Can patients undergoing chemotherapy safely take medical-grade manuka honey?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Patients Getting Chemo Take Manuka Honey?

Patients undergoing chemotherapy can safely take medical-grade manuka honey, but the evidence does not support its use for preventing or treating chemotherapy-induced mucositis, and compliance is often poor due to tolerability issues.

Safety Profile

Medical-grade manuka honey has been demonstrated to be safe in healthy individuals, with no allergic responses (measured by IgE levels), no changes to gut microbiota, and no accumulation of advanced glycation end products 1. This safety profile extends to cancer patients, as multiple clinical trials have enrolled chemotherapy patients without significant safety concerns beyond tolerability issues 2, 3, 4.

Efficacy Evidence: The Reality Check

The evidence for manuka honey's effectiveness in chemotherapy-related complications is disappointing:

Oral Mucositis

  • A randomized placebo-controlled trial of 106 head and neck cancer patients receiving radiation (62% with concurrent chemotherapy) found no statistically significant difference between manuka honey and placebo gel for radiation-induced oral mucositis across multiple validated scales (RTOG, WHO, Oral Mucositis Assessment Scale) 2
  • Another double-blind RCT of 131 patients similarly found no significant difference between manuka honey and placebo (golden syrup) in preventing or treating radiation-induced mucositis 4

Radiation Esophagitis

  • The NRG Oncology RTOG 1012 phase 2 trial randomized 163 lung cancer patients to supportive care, liquid manuka honey, or honey lozenges during chemoradiation 3
  • No significant difference was found in the primary endpoint (pain on swallowing at 4 weeks) or most secondary endpoints
  • The only significant finding was slightly less opioid use in the supportive care arm compared to liquid honey (opposite of the intended benefit)

The Tolerability Problem

A critical limitation across all studies was poor patient compliance:

  • Dropout rates of 52-57% were common, primarily due to nausea 2
  • Compliance became particularly problematic after mucositis onset 4
  • Many patients could not tolerate the study products for more than 1 week 2

This poor tolerability undermines any theoretical benefit and represents a practical barrier to use during chemotherapy when patients already experience significant nausea and taste changes.

Guideline Perspective on CAM Use

The 2022 National Cancer Institute guideline on complementary and alternative medicine (CAM) use in cancer patients provides a framework for addressing such questions 5. Healthcare providers should:

  • Actively assess CAM use using structured approaches (the SCOPED framework: Situation, Choices, Objectives, People, Evaluate, Decision)
  • Present evidence in an unbiased manner, acknowledging what is known and unknown
  • Recognize that 61.7% of patients do not disclose CAM use to providers unless specifically asked 6
  • Provide credible, evidence-based information to support informed decision-making

Clinical Recommendation

If a patient wishes to use manuka honey during chemotherapy:

  1. Acknowledge safety: Medical-grade manuka honey (UMF 20+ or equivalent) is safe to consume
  2. Set realistic expectations: Explain that high-quality randomized trials show no benefit for mucositis prevention or treatment
  3. Warn about tolerability: Inform patients that 50-60% of chemotherapy patients cannot tolerate it due to nausea and taste issues
  4. Suggest alternatives: Direct patients toward evidence-based interventions for mucositis management (oral care protocols, cryotherapy for specific regimens, benzydamine mouthwash for head/neck radiation) 7
  5. Document use: Record the patient's decision to use honey to ensure comprehensive medication reconciliation

Common Pitfalls to Avoid

  • Don't dismiss outright: Patients may interpret dismissal as lack of support for their autonomy
  • Don't overstate risks: While ineffective for mucositis, manuka honey is safe
  • Don't assume patients will volunteer information: Actively ask about all supplements and natural products 5, 6
  • Don't confuse earlier promising case reports with current RCT evidence: The systematic review from 2008 8 suggested potential benefits, but subsequent rigorous trials failed to confirm these findings

The evidence is clear: while safe, manuka honey offers no proven benefit for chemotherapy-related complications and is often poorly tolerated when patients need it most.

References

2
Research

A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014

Related Questions

Is Manuka honey safe and effective for treating minor wounds or sore throat in healthy adults?
What is the optimal dosage and duration of manuka honey supplementation for gut health?
Is Manuka honey a good alternative to white sugar for daily consumption?
What is the optimal timing and frequency for taking manuka honey for gut health, in relation to meals?
Why is Sublocade (buprenorphine) preferred over monthly Brixadi (buprenorphine/naloxone sublingual film) for a patient who needs a long‑acting injectable and has difficulty with sublingual administration?
Is tight control of cardiovascular disease risk factors required when a patient has multiple risk factors?
What is the recommended management for a newly diagnosed follicular thyroid carcinoma in an adult?
What is the recommended third‑line therapy after failure of rituximab plus lenalidomide (R2) in relapsed/refractory follicular lymphoma?
What are the indications and dosing regimen for Keflex (cephalexin) in an adult without drug allergies, renal or hepatic impairment?
In a patient taking nifedipine 60 mg daily and hydrochlorothiazide 25 mg daily who still has elevated blood pressure, what is the next step in management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.